drugset
drugset / Trial / NCT05876767

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

NCT05876767 ↗

Phase 1 Completed 76 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This phase 1 study will assess the safety and tolerability, and characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of SAR444336 in healthy subjects following single- and repeated-dose administrations as a first step in clinical development prior to administering this new investigational medicinal product (IMP) to patients.

Timeline

Start
2021-10-15
Primary completion
2023-12-12
Completion
2023-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SAR444336 Unknown — Subcutaneous

Indications

No indication recorded.